Tufts examines $2.87bn product lifecycle cost per approved drug

By Melissa Fassbender

- Last updated on GMT

According to Tufts, the average product lifecycle cost per approved drug is $2.870bn. (Image: iStock)
According to Tufts, the average product lifecycle cost per approved drug is $2.870bn. (Image: iStock)
Tufts Center for the Study of Drug Development has released an assessment of the cost to develop and win marketing approval for a new drug.

The analysis, which was recently published​ in the Journal of Health Economics, estimated the average cost to develop and gain marketing approval for a new drug at $2.558bn.

This figure was calculated based on estimated average out-of-pocket costs ($1.395bn) and times costs ($1.163bn) – the “expected returns that investors forego while a drug is in development​,” according to the report.

However, according to Tufts CSDD, when $312m in post-approval R&D costs are included, the average product lifecycle cost per approved drug increases to $2.870bn.

Additionally, the estimate accounts for expenses suffered during product development efforts that fail, which, as Outsourcing-pharma.com previously reported​, has become an increasing problem in the industry.

The researchers also used information provided by 10 pharmaceutical companies on 106 randomly selected drugs that were first tested in human subjects between 1995 and 2007.

Out-of-pocket clinical costs

Joseph A. DiMasi, director of economic analysis at Tufts CSDD and the study’s principal investigator, also explained that the primary reason behind rising drug development costs​ is out-of-pocket costs for individual drugs and higher failure rates for drugs tested in human subjects.

According to the report, out-of-pocket clinical costs are increasing because of greater clinical trial complexity, larger trial sizes, and higher input costs from the medical sector used for development.

Changes in protocol design are also increasing these costs, as efforts are being made to collect health technology assessment information, in addition to supplementary tests that are being carried out on comparator drugs to gather comparative effectiveness data in response to payer demand.

"Drug developers are taking action to rein in rising development costs,” ​added DiMasi, “including increasing efforts to discover, validate, and use biomarkers, adopting new approaches to patient recruitment and retention, and implementing leading-edge project management practices, but they face strong headwinds, given the complexity of the problems they're addressing​.”

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Products

View more

Webinars